Serum amylase and C-reactive protein in risk stratification of pancreas-specific complications after pancreaticoduodenectomy by Palani Velu, L.K. et al.
  
 
 
 
 
Palani Velu, L.K., McKay, C.J., Carter, C.R., McMillan, D.C., Jamieson, N.B., and 
Dickson, E.J. (2016) Serum amylase and C-reactive protein in risk stratification of 
pancreas-specific complications after pancreaticoduodenectomy. British Journal of 
Surgery, 103(5), pp. 553-563. 
 
There may be differences between this version and the published version. You are 
advised to consult the publisher’s version if you wish to cite from it. 
 
 
 
 
 
 
http://eprints.gla.ac.uk/118764/ 
     
 
 
 
 
 
 
Deposited on: 02 May 2016 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enlighten – Research publications by members of the University of Glasgow 
http://eprints.gla.ac.uk 
 1 
Serum Amylase and CRP in Risk Stratification of Pancreas-Specific 1 
Complications After Pancreaticoduodenectomy 2 
Lavanniya K. Palani Velu, MRCS1,2, Colin J. McKay, MD1, C. Ross Carter, MD1,  3 
Donald C. McMillan, PhD2, Nigel B. Jamieson, PhD1,2, and Euan J. Dickson, MD1 4 
Affiliations 5 
1West of Scotland Pancreatic Unit; Glasgow Royal Infirmary, Glasgow, G31 2ER, UK 6 
2The Academic Department of Surgery, University of Glasgow, Glasgow Royal 7 
Infirmary, Glasgow, G31 2ER, UK 8 
 9 
Contact for correspondence and reprints:  10 
Mr Nigel B Jamieson 11 
 Level 2, 12 
New Lister Building, 13 
Glasgow Royal Infirmary, 14 
10-16 Alexandra Parade, 15 
Glasgow G31 2ER 16 
Tel: +44-141-211-8655     17 
E-mail: nigel.jamieson@glasgow.ac.uk 18 
 19 
Category: Original article 20 
 21 
This work has previously been presented in part at the Great Britain and Ireland 22 
Hepato Pancreato Biliary Association Scientific Meeting on the 13th of March 2014. 23 
  24 
25 
 2 
ABSTRACT 1 
 2 
Background 3 
Pancreas-specific complications (PSC), comprising postoperative pancreatic fistula, 4 
haemorrhage, and intra-abdominal collections, are drivers of post 5 
pancreaticoduodenectomy (PD) morbidity and mortality. Postoperative day 0 (PoD0) 6 
serum amylase ≥ 130 IU/L has been shown to be an objective surrogate of 7 
pancreatic texture, a determinant of PSC. This study evaluated serial measurements 8 
of C-reactive protein(CRP) to refine PSC risk stratification. 9 
Methods 10 
Consecutive patients undergoing PD between 2008 and 2014, with vascular 11 
resection if required and without prior chemoradiotherapy, had serum investigations 12 
performed from the pre-operative day until discharge. Receiver operating 13 
characteristic (ROC) analysis was used to identify a threshold value of serum CRP 14 
with clinically relevant PSC as an outcome measure up to 30 days post-discharge. 15 
Results 16 
Of 230 patients who were included, 95 (41.3%) patients experienced a clinically 17 
relevant PSC. Post-operative day 2 (PoD2) serum CRP ≥180 mg/L was associated 18 
with PSC, prolonged critical care stay, and relaparotomy (all P ≤ 0.05). Patients with 19 
a PoD0 serum amylase ≥ 130 IU/L who developed a PoD2 serum CRP ≥ 180 mg/L 20 
had a higher incidence of morbidity. Patients were stratified into High, Intermediate 21 
and Low risk groups using these markers. The Low-risk category was associated 22 
with a Negative Predictive Value of 86.8% for clinically relevant PSC development. 23 
There were no mortalities (0/52; 0%) in the Low-risk group, with seven deaths (7/79; 24 
9.4%) in the High-risk group. 25 
Conclusions 26 
A Low-risk profile, (PoD0 serum amylase <130 IU/L and PoD2 serum CRP <180 27 
mg/L), may identify patients suitable for safe and early discharge following 28 
pancreaticoduodenectomy.  29 
 3 
INTRODUCTION 1 
Pancreaticoduodenectomy (PD) remains the preferred resectional procedure for 2 
malignant and benign disorders of the pancreatic head and the peri-ampullary 3 
region. Although previously associated with high postoperative mortality, service 4 
centralisation, innovations in surgical technique and advances in perioperative 5 
management have successfully reduced this to 5% or less in high-volume centres.1, 2 6 
Despite these measures, post-PD morbidity rates remain high at 40–50%.3, 4  7 
 8 
Development of a postoperative pancreatic fistula (POPF) following pancreatic 9 
resection is the most important complication, associated subsequently with post-10 
pancreatectomy haemorrhage (PPH) and intra-abdominal collections (IAC).5,6 These 11 
pancreas-specific complications (PSC), a composite term, contribute to severe 12 
postoperative morbidity and potentially perioperative mortality.7  13 
 14 
A soft pancreatic remnant, a small pancreatic duct, along with a high intra-operative 15 
blood loss are major risk factors for POPF.8 These risk factors have been 16 
aggregated into a Fistula Risk Score (FRS) which was validated in independent 17 
cohorts.9 The present authors have previously shown that raised serum amylase on 18 
the night of surgery (postoperative day 0 [PoD0]) serves potentially as an objective 19 
risk factor for the development of clinically relevant (CR)-POPF, return to theatre and 20 
readmission to a critical care environment.10 This may add objectivity to the 21 
subjective intra-operative assessment of risk components for POPF. 22 
 23 
C-reactive protein (CRP), has previously been shown to predict postoperative 24 
morbidity following oesophageal, gastric, and colorectal resections.11, 12 Although 25 
evidence exists to support the utility of serum CRP in the prediction of postoperative 26 
 4 
morbidity following pancreatic resections, it is less clear if the serial assessment of 1 
serum CRP can function as a robust trigger to inform clinical decision making.  2 
 3 
This study sought to determine serum CRP levels in the immediate postoperative 4 
period, and the relationship between CRP, PoD0 serum amylase levels and 5 
established risk factors for postoperative morbidity following PD, in an effort to 6 
optimise risk prediction and individualise patient management.   7 
 5 
MATERIALS AND METHODS 1 
Patients 2 
In this prospective study all patients underwent either classical or pylorus-preserving 3 
PD (PPPD) in the West of Scotland Pancreatic Unit, Glasgow Royal Infirmary, 4 
Glasgow, UK, during a 6-year period (January, 2008 to January, 2014) by one of 5 
three surgeons for malignant and benign disease. Resectability for malignant 6 
disease was classified in accordance with  trial inclusion criteria,13 and outlined 7 
previously.14  8 
Prospective Data Collection  9 
Demographic, pathological and therapeutic data were recorded on a prospective 10 
database populated from a combination of electronic patient records, preoperative 11 
imaging and anaesthetic charts. Preoperative clinical data included age, sex, body 12 
mass index (BMI), preoperative biliary drainage and serum investigations including 13 
amylase, bilirubin and CRP. The Physiological and Operative Severity Score for the 14 
enUmeration of Mortality and morbidity (POSSUM) physiology score was calculated 15 
as an objective measure of co-morbidity and preoperative physiology.15 Preoperative 16 
CT images were assessed to calculate pancreatic duct diameter at the line of 17 
transection of the pancreas anterior to the portal vein.  18 
Intra-operative data collection included ASA status, reconstruction technique and 19 
texture of the pancreatic remnant. Postoperatively the specimens were dichotomised 20 
into either pancreatic ductal adenocarcinoma (PDAC) and chronic pancreatitis or 21 
other pathology (including ampullary carcinoma, cholangiocarcinoma, duodenal 22 
carcinoma, neuroendocrine tumours, and cystic lesions).   23 
 6 
Outcome data included length of stay in a critical care environment, (defined as 1 
either Level II or III care) and total length of postoperative hospital stay. Data for 2 
readmission to Glasgow Royal Infirmary were also recorded. All postoperative 3 
complications were prospectively recorded up to 30 days following discharge and 4 
graded through detailed weekly consensus discussion by the three operating 5 
pancreatic surgeons according to the International Study Group of Pancreatic 6 
Surgery (ISGPS) classifications and the Dindo-Clavien classification. 16-18. Mortality 7 
was recorded at 30 and 90-days.  8 
Operative Procedure 9 
Invasive monitoring (central venous, arterial and urinary catheters)  and nasogastric 10 
tubes (NGTs) were inserted after induction of anaesthesia. All patients received 11 
preoperative intravenous (IV) antibiotics as prophylaxis for surgical site infection. A 12 
short-acting somatostatin analogue was commenced intra-operatively and continued 13 
for 5 days subcutaneously (Octreotide 100 µg, Sun Pharmaceuticals, UK) with a 14 
proton-pump inhibitor continued indefinitely. The operative steps of PD and 15 
histological analysis were performed as described previously.14 The extent of 16 
resection remained constant during this study. With regards to resections for 17 
malignant disease, lesions within the uncinate process or those sited medially would 18 
undergo an “artery first” exploration to determine arterial involvement, whereas 19 
lesions at the neck underwent an early dissection of the hepaticoduodenal ligament 20 
to ensure proximal clearance. Short segment (<180°) venous involvement was 21 
managed by en bloc resection and primary anastomosis if necessary.  22 
Pancreatic transection was performed with scalpel, ultrasonic scalpel or diathermy 23 
depending on operator preference. The pancreatic remnant was anastomosed using 24 
a dual-layer, duct-to-mucosa technique either to jejunum (pancreaticojejunostomy, 25 
 7 
[PJ]) or stomach (pancreaticogastrostomy, [PG]). The choice of PJ or PG 1 
anastomosis was based on surgeon preference and not allocated according to risk of 2 
postoperative complications. Over the study period there was a trend to increased 3 
use of PG formation. Pancreatic duct stents were not routinely used. Absorbable 4 
synthetic monofilament sutures (BiosynTM, Covidien) were used for both techniques, 5 
with 4/0 sutures for the PJ and 3/0 sutures for the PG. Hepaticojejunostomy and 6 
gastrojejunostomy were performed in a standard fashion. At the end of the 7 
procedure, one or two non-suction drains were routinely placed adjacent to the 8 
pancreatic and biliary anastomosis.  The stump of the gastro-duodenal artery was 9 
not covered routinely. 10 
Perioperative Management 11 
In the immediate postoperative period all patients were admitted to the surgeon-led 12 
SHDU (Level II care). Patients requiring a higher level of care were admitted to the 13 
Intensive Care Unit (Level III).  14 
Perioperative care of patients was directed by the operating surgeon. Serum 15 
laboratory measurements were performed daily from the pre-operative day until 16 
discharge. Patients were allowed sips of clear fluid from the night of surgery with oral 17 
intake increased as tolerated. Parenteral nutrition was not instituted routinely. 18 
Invasive monitoring was ceased based upon the patients clinical progress. Practice 19 
at this institution favours routine drain placement with early removal on the morning 20 
of PoD1 based on measurement of PoD0 serum amylase. 21 
Management of suspected POPF included antibiotics, image-guided percutaneous 22 
drainage, or surgical exploration with extensive peripancreatic drainage or 23 
completion pancreatectomy. Over the study period there was a trend towards re-24 
laparotomy and establishing extensive peripancreatic drainage if patients required a 25 
 8 
return to theatre. IACs were diagnosed on the basis of clinical observations, and 1 
serum investigations, with cross-sectional imaging confirmation. Management 2 
involved antibiotics, percutaneous drainage and if necessary, surgical exploration 3 
and open drainage. PPH was usually managed with blood transfusion and early 4 
angiography with or without coil embolisation or vascular stenting. Endoscopy or re-5 
laparotomy was reserved for patients where angiography did not provide adequate 6 
haemostasis.  7 
Definitions of Outcome Measures 8 
The upper normal limit for serum amylase at this institute is 100 IU/L. The upper 9 
normal limit for serum CRP is 10mg/L. A drain fluid amylase three times the serum 10 
amylase on or after PoD3 was diagnostic of POPF in accordance with ISGPS 11 
definitions.17  12 
Intra-abdominal collections (IAC) were defined as any major intra-abdominal fluid 13 
collection found on cross-sectional imaging, associated with any of the following: 14 
raised inflammatory markers, pyrexia, contiguous drain or wound discharge, or 15 
increasing abdominal pain. Post-pancreatectomy haemorrhage was defined by the 16 
ISGPS.18 PSC is a composite term capturing POPF, PPH, or IAC. Patients who 17 
experienced more than one PSC had the event of greater severity recorded as the 18 
PSC, and the event of lesser severity recorded in the appropriate complication 19 
category (POPF, IAC or PPH). Complications of Dindo-Clavien Grade II and 20 
greater16 were classed as CR as were complications graded as ISGPS Grades B or 21 
C.   22 
Statistical Analysis 23 
 9 
Continuous data are presented as a median (range). Categorical variables were 1 
compared using the χ2 test. The Mann-Whitney U test was used to compare 2 
continuous variables between two groups while the Kruskal-Wallis test was used to 3 
compare between multiple groups. The diagnostic accuracy of serum CRP in 4 
predicting adverse postoperative outcomes was assessed with Receiver Operating 5 
Characteristic (ROC) analysis.  6 
Univariable binary logistic regression analysis with calculation of odds ratios (OR) 7 
and 95% confidence intervals (CI) was used to explore the association between 8 
demographic, perioperative clinicopathological factors, including PoD0 serum 9 
amylase and the risk of complications, in particular PSC. Multivariable binary logistic 10 
regression analysis was performed on variables showing a significant association on 11 
univariable analysis (P<0.05). Backward stepwise regression was used starting with 12 
a saturated model and variables with a P>0.1 excluded at each step until no more 13 
variables could be excluded. List-wise deletion was performed in cases with missing 14 
data. Statistical significance was set at P<0.05. All statistical analysis was performed 15 
using SPSS version 20.0 (IBM, Armonk, NY).   16 
 10 
RESULTS 1 
Clinicopathological Characteristics of the Study Cohort 2 
230 patients underwent PD in the study period. Table 1 summarises the cohort’s 3 
demographic, operative, pathologic and treatment characteristics. None of the 4 
patients received pre-operative chemoradiotherapy. Median length of drain 5 
maintenance was 3 days (IQR 2 - 8 days).  6 
Postoperative Complications 7 
The complication profile of the study cohort is detailed in Table 1. The overall 8 
complication rate was 69.1% (Dindo-Clavien grades I-V) with the complication rate 9 
graded Dindo-Clavien II and higher equal to 57.8%. Ninety-five (41.3%) patients 10 
experienced at least one CR-PSC. Twenty-two patients (9.6%) experienced a chyle 11 
leak; the majority of these patients also experienced a CR-PSC. Thirteen patients 12 
(5.7%) experienced a biliary fistula, the majority of whom did not require a 13 
postoperative intervention.  14 
 15 
Thirty-one patients (13.5%) required a re-laparotomy; of these 5 patients (2.2%) 16 
required a completion pancreatectomy. One patient (0.4%) returned to theatre for re 17 
- laparotomy and arrest of haemorrhage from the liver bed, and one patient returned 18 
to theatre for a washout and re-suturing of a dehisced wound. Twenty-four patients 19 
(10.4%) returned to theatre for a laparotomy, and establishment of wide 20 
peripancreatic drainage for source control of sepsis.  21 
 22 
Five (2.2%) deaths occurred as a consequence of PPH and associated 23 
complications, two (0.9%) as a result of infected IACs, two (0.9%) as a result of 24 
 11 
multi-organ failure and one (0.5%) following a postoperative myocardial infarction. 1 
Nine of the ten patients (90%) who died developed ISGPF Grade C POPF. 2 
 3 
CRP, Pancreas-Specific Complications, Length of Stay and Mortality 4 
Serial serum CRP measurements of patients who developed clinically relevant 5 
complications were compared to those who did not experience a complication 6 
(Supplementary Table 1). Patients who developed CR-POPF or CR-PSC had a 7 
higher median serum CRP from PoD2. The influence of PoD0 serum amylase and 8 
texture of the pancreatic remnant on the serial expression of serum CRP is 9 
illustrated in Supplementary Figure 1.  10 
 11 
ROC analysis determined threshold values of CRP associated with CR-PSC (Figure 12 
1A) and CR-POPF (Figure 1B). A PoD2 CRP of 180mg/L was most closely 13 
associated with CR-PSC (AUC=0.648, 95%CI: 0.58-0.72, sensitivity 81.5%, 14 
specificity 40.3%, negative predictive value [NPV] of 75.3% for PSC, P<0.001) while 15 
a PoD2 CRP of 230mg/L was most closely associated with CR-POPF (AUC=0.682, 16 
95%CI: 0.60–0.76, sensitivity 61.1%, specificity 61.9%, P<0.001).  17 
 18 
Patients with a PoD2 CRP≥180mg/L were more likely to develop clinically relevant 19 
PSC, POPF, IAC, PPH, require invasive postoperative intervention or relaparotomy 20 
(All P<0.05) (Table 2). There was a trend towards higher 90-day mortality rate 21 
associated with a PoD2 CRP≥180mg/L (5.7% vs. 1.4% , P=0.132). PoD2 CRP 22 
≥180mg/L was not associated with non-pancreatic complications including 23 
cardiorespiratory, or wound infections. Increasing severity of Dindo-Clavien graded 24 
PSC was associated with a rise in median PoD2 serum CRP (Supplementary Figure 25 
2).  26 
 12 
Prediction of Clinically Relevant Pancreas-Specific Complications 1 
The relationships between preoperative characteristics, intra-operative factors, post-2 
operative biochemical markers and the development of CR-PSCs are shown in 3 
Supplementary Table 2. Significant univariable factors included small pancreatic 4 
duct, soft pancreatic texture, PoD0 amylase>130IU/L and PoD2 CRP ≥180mg/L (all 5 
P<0.05).  6 
On multivariable analysis, soft pancreatic texture, PoD0 amylase>130IU/L and PoD2 7 
CRP ≥180mg/ were independent predictors of CR-PSC (Table 3). 8 
 9 
Predictors of Postoperative Serum CRP levels 10 
Univariable logistic regression determined BMI>25 kg/m2, pancreatic duct ≤ 3mm, 11 
soft pancreatic remnant, non-PDAC/chronic pancreatitis pathology, serum bilirubin 12 
>250 mmol/L and PoD0 serum amylase ≥130 IU/L as factors associated with a PoD2 13 
CRP≥180 mg/L (all P<0.05) (Supplementary Table 3). When included in the 14 
multivariable model, only small pancreatic duct and PoD0 serum amylase≥130 IU/L 15 
were independent predictors.  16 
Objective risk stratification  17 
In order to simplify post – PD risk stratification, patients were grouped into low, 18 
intermediate and high-risk categories for developing CR-PSC according to PoD0 19 
serum amylase and PoD2 serum CRP as follows; Low-risk: PoD0 serum amylase 20 
<130 IU/L and PoD2 CRP <180 mg/L (n=52 [22.6%]). High-risk: PoD0 serum 21 
amylase ≥130 IU/L and PoD2 CRP ≥180mg/L (n=79 [34.3%]). Intermediate-risk: 22 
PoD0 serum amylase<130 IU/L and PoD2 CRP ≥180mg/L or PoD0 serum 23 
amylase≥130 IU/L and PoD2 CRP < 180mg/L (n=83 [36.1%]) (Supplementary Table 24 
4). The High and Intermediate risk groups included significantly more patients with 25 
soft textured glands, small pancreatic ducts, and other pathology. 26 
 13 
The High-risk group identified patients at an elevated risk of CR-PSC when 1 
compared to the Intermediate-risk group. Moreover, there was a trend towards an 2 
increase in the 90-day mortality rate (8.9% vs. 2.4%) associated with the High 3 
compared to Intermediate risk group with no deaths occurring in the Low-risk group 4 
(Figure 2). Likewise the Intermediate-risk group experienced a significantly worse 5 
complication profile compared to the Low-risk group, with a greater frequency of CR-6 
PSC, POPF, and more frequent invasive postoperative interventions. Furthermore, 7 
increasing risk category was associated with lengths of hospital stay beyond 15 days 8 
and critical care stay beyond 7 days.   9 
The Low-risk category was associated with a negative predictive value (NPV) of 10 
86.5% for the development of CR-PSC with a negative likelihood ratio (LR-) of 0.19 11 
compared the intermediate/High-Risk categories. The High-risk category had a PPV 12 
of 65.8% for the development of CR-PSC with a LR+ of 2.35 compared to the rest of 13 
the cohort. This risk categorisation tool remained a predictor of PSC following 14 
stratification by remnant gland texture (Figure 2).  15 
 14 
DISCUSSION 1 
The present study shows that, in addition to PoD0 serum amylase, an elevated PoD2 2 
serum CRP is associated with clinically relevant pancreas-specific complications. 3 
Taken together, these simple serum investigations can stratify the risk for CR-PSC 4 
following PD. Incorporating intra-operative data of the organ response (as assessed 5 
by PoD0 serum amylase) and the host response to the surgical procedure (PoD2 6 
serum CRP), the current analysis determined three risk groups with an increasing 7 
probability of developing CR-PSC. Most significantly, this analysis demonstrated a 8 
high NPV (86.8%) for CR-PSC for patients in the Low-risk category.  9 
The rate of significant complications and mortality after PD in the present cohort is 10 
broadly in keeping with established literature.19 POPF  is not the only determinant of 11 
severe morbidity post-PD. Overall morbidity or CR-PSC that can increase mortality 12 
and translate into prolonged inpatient hospital stay, readmission and greater 13 
economic burden should become the focus of risk stratification following PD. PSC 14 
represents a useful composite term capturing not only overt POPF but also major 15 
consequences of fistulae that were not clinically obvious.20   16 
The utility of PoD0 serum amylase as an objective marker to identify patients with a 17 
low-risk of a CR-POPF (ISGPS B/C) has been demonstrated previously.10 A recent 18 
study revealed similar results with an elevated PoD1 serum amylase as an 19 
independent predictor of POPF.21 In an effort to further refine risk stratification post-20 
PD, the utility of postoperative serum CRP was investigated as a tool to identify 21 
patients potentially suitable for rapid recovery and safe, early discharge. 22 
The association between a raised postoperative serum CRP and clinically relevant 23 
anastomotic leakage has been demonstrated in colorectal and oesophageal 24 
surgery.11, 12 A study of serum CRP in patients who had undergone PD 25 
 15 
recommended a PoD4 serum CRP cut-off of 140mg/L to predict general inflammatory 1 
complications.22 Uemura et al  proposed that PoD4 CRP of 156mg/L and non-serous 2 
fluid in abdominal drains was associated with CR-POPF,23 while Ansorge et al  3 
utilised a combination of drain amylase and elevated PoD3 serum CRP.24 The latter 4 
study provided strong evidence for serum CRP predicting postoperative 5 
complications yet was limited as intra-operative predictors of POPF including 6 
pancreatic texture and duct size were not considered. 7 
A risk stratification tool is of clinical utility if it has potential to impact patient 8 
management. A risk-stratified perioperative management algorithm could be 9 
constructed utilising PoD0 serum amylase and PoD2 serum CRP. Patients in the Low-10 
risk category could be considered suitable for cessation of invasive monitoring, drain 11 
removal and rapid step-down from a level II critical care environment. The clinician 12 
would also be aware of the increased risk of latent CR-PSC in the Intermediate and 13 
High-risk groups, informing clinical decision making beyond PoD2.  14 
The controversy regarding drainage continues to impact the perioperative 15 
management of patients undergoing PD. Concern has arisen regarding a 16 
standardised no-drain policy, notably, in a study by Correa-Gallego et al, where 17 
mortality was increased (1% vs. 3%, P=0.02) when routine drainage was eliminated 18 
following PD.25 Furthermore, a recent randomised multicenter trial concluded that 19 
elimination of drainage increases severity and frequency of complications, and may 20 
have contributed to increased mortality.26 If absence of drainage increases mortality 21 
risk, then a compromise may be that of routine drainage in all PDs followed by 22 
selective, early and safe drain removal in order to minimise drain-associated 23 
morbidity. Selective drain placement is an alternative strategy, however, this is 24 
based on subjective assessment of pancreatic texture.8. 25 
 16 
Pancreatic texture has previously been identified as the principal determinant of an 1 
elevated CRP following PD.27 Independent factors related to an elevated PoD2 CRP 2 
in this study were a small pancreatic duct, and PoD0 serum amylase≥130IU/L. 3 
Notably neither preoperative jaundice nor biliary drainage correlated with 4 
postoperative CRP suggesting that bacteraemia related to biliary tract obstruction or 5 
manipulation was not an important factor. The mechanism underlying 6 
hyperamylaesemia post-PD also remains unclear. While this may represent 7 
extravasation of pancreatic secretions with systemic absorption; postoperative 8 
hyperamylaesemia could potentially represent pancreatitis of the normal pancreatic 9 
remnant, which subsequently predisposes to anastomotic failure.28 Obstruction of the 10 
pancreatic duct at the anastomosis due to haemorrhage, or suture placement, are 11 
also potential explanations.  12 
In patients with a high PoD0 serum amylase, there was a failure of the expected 13 
normalisation of CRP after 48hrs, with the majority of patients who subsequently 14 
developed a CR-PSC maintaining a raised CRP by PoD6. While this could indicate a 15 
proportionate rise of serum CRP in the context of post-PD pancreatitis, an elevation 16 
of PoD2 serum CRP beyond the 180mg/L threshold in patients with a low PoD0 17 
serum amylase could indicate a disproportionate immune response to the surgical 18 
insult of a PD.  19 
Traditionally, a rise in serum CRP is considered to be due to, rather than the cause 20 
of postoperative complications. Emerging evidence suggests that CRP may play a 21 
role in bridging the innate and adaptive immune systems by assisting complement-22 
binding and phagocytosis.29 High levels depress T-lymphocyte function, exaggerate 23 
the stress response and hyperglycaemia30 with the latter factors vital in promoting 24 
bacterial growth and development of infective postoperative complications.31  25 
 17 
Limitations 1 
Despite the retrospective nature of the analysis, the data generated through 2 
examination of routine serum biochemical tests are informative. All patients in this 3 
cohort received octreotide as prophylaxis for POPF. Evidence for the utility of 4 
somatostatin analogues in pancreatic surgery is conflicting.32, 33 However, based on 5 
best available evidence, octreotide is administered as part of the peri-6 
pancreatectomy management strategy at this and other institutions.34 Decreasing 7 
diameter of the pancreatic duct is associated with increasing risk of CR-POPF and 8 
post-PD morbidity.8 However the size of the present cohort precluded the analysis of 9 
this factor. A recent study demonstrated that POD1 amylase <600U/L was 10 
associated with absence of POPF.35 This would suggest that drain amylase levels on 11 
PoD1 and PoD3 could enhance PSC risk prediction. However, the measurement of 12 
drain amylase levels was often limited by haemolysis in the majority of patients. This 13 
study was unable to provide data with regards to the day when the CR-PSC became 14 
clinically apparent, limiting the analysis with regard to the time-lag between 15 
availability of risk-stratification and diagnosis of CR-PSC. Delayed gastric emptying 16 
(DGE), was poorly recorded prior to 2012, and was not included in the analysis. 17 
Compared to assessment based on pre- and intra-operative factors alone, the 18 
current study is limited as scoring requires review at PoD2. However, this reflects an 19 
opportune time point for informed, clinically triggered postoperative management 20 
decisions regarding drain management, nutrition, and critical care step-down. Finally, 21 
an external cohort was not utilised for validation.  22 
In conclusion, the results of the present study suggest that routine, postoperative 23 
measurements of serum amylase and CRP can provide a risk stratification tool for 24 
clinically relevant pancreas-specific complications following 25 
pancreaticoduodenectomy.  26 
 18 
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Table 1. Demographic, operative, pathological and postoperative outcome characteristics for 230 patients 
undergoing pancreaticoduodenectomy. 
Characteristics n (%) 
Demographics 
Age (years)1 ≤ 60 100 (43.5) 
 > 60 130 (56.5) 
Sex Female 79 (34.4) 
 Male 151 (65.7) 
BMI (kg/m2) < 25 97 (42.2) 
 ≥ 25  126 (54.8) 
Smoking No 134 (58.3) 
 Yes 71 (30.9) 
POSSUM Score2  ≤ 16 114 (49.6) 
 > 16 97 (42.2) 
ASA I 30 (13.0) 
 II 135 (58.7 
 III 35 (15.2) 
IV 2 (0.9) 
Bilirubin (mmol/L) ≤ 250 197 (85.7) 
 > 250 33 (14.3) 
Pre-operative Biliary Drainage No 129 (56.1) 
 Yes 101 (43.9) 
Operative 
Procedure PPPD 69 (30.0) 
 Classical 161 (70.0) 
Vein Resection No 193 (83.9) 
 Yes 37 (16.1) 
Pancreatic Anastomosis Pancreaticogastrostomy 51 (22.2) 
 Pancreaticojejunostomy 176 (76.5) 
Pancreatic Texture Hard 97 (42.2) 
 Soft 94 (40.9) 
Pancreatic Duct Diameter (mm) > 3 141 (61.3) 
 ≤ 3 80 (34.8) 
Estimated Blood Loss (ml)3 < 1450 121 (56.3) 
 ≥ 1450 94 (43.7) 
Pathology PDAC 83 (36.1) 
 Ampullary adenocarcinoma 41 (17.8) 
 Cholangiocarcinoma 31 (13.5) 
 Chronic pancreatitis 17 (7.4) 
 Neuroendocrine tumor 14 (6.1) 
 IPMN 13 (5.7) 
 Duodenal adenocarcinoma 12 (5.2) 
 Other 18 (7.8) 
Postoperative Outcome 
Pancreas-specific Complication4 Grade 0 - I 135 (58.7) 
 Grade II - V 95 (41.3) 
Postoperative Pancreatic Fistula4 Grade 0 - I 176 (76.5) 
 Grade II - V 54 (23.5) 
Intra-abdominal Collection4 Grade 0 - I 160 (69.6) 
 Grade II - V 70 (30.4) 
Post-pancreatectomy Haemorrhage4 Grade 0 - I 203 (88.3) 
 Grade II - V 27 (11.7) 
Cardiorespiratory  Complication4 Grade 0 - I 181 (78.7) 
 Grade II - V 49 (21.3) 
Wound infection4 Grade 0 - I 194 (84.3) 
 Grade II - V 36 (15.7) 
Invasive Intervention No 176 (76.5) 
 Yes 54 (23.5) 
Reoperation No 199 (86.5) 
 Yes 31 (13.5) 
Readmission to Critical Care No 175 (76.1) 
 Yes 47 (20.4) 
Length of Stay (days) Critical Care  7.0 (5.0–10.0)5 
 Overall 15.0 (11.8–25.0)5 
Hospital readmission (30-day)  47 (20.4) 
Mortality (30-day)  6 (2.6) 
Mortality (90-day)  10 (4.3) 
1 Mean age 60 years. 
2 Median POSSUM score was 16. 
3 Median estimated blood loss was 1450ml ( IQR 803 - 2000 ml).  
4 Grade refers to the Dindo-Clavien scale of postoperative complications.  
5 Median and interquartile range.    
BMI - Body Mass Index, POSSUM - Physiological and Operative Severity Score for the enUmeration of Mortality and 
morbidity (median = 16), PPPD - Pylorus-preserving pancreaticoduodenectomy, PDAC - pancreatic ductal 
adenocarcinoma, IPMN - intraductal papillary mucinous neoplasm, Other  - miscellaneous tumour types. 
 
Table 2. Relationship between PoD2 serum CRP and postoperative outcomes following 
pancreaticoduodenectomy (n = 230). 
 
 
 
Category 
CRP < 180mg/L 
N (%) 
73 (31.7) 
CRP ≥ 180mg/L 
N (%) 
157 (68.3) 
P 1 
Pancreas-specific complications2 Grade 0 – I  55 (75.3) 80 (51.0)  
 Grade II – V 18 (24.7) 77 (49.0) <0.001 
Postoperative pancreatic Fistula 3 No 61 (83.6) 96 (61.1)  
 Grade A 3 (4.1) 16 (10.2)  
 Grade B 5 (6.8) 28 (17.8)  
 Grade C 4 (5.5) 17 (10.8) 0.007 
Intra-abdominal collection2 Grade 0 – I 61 (83.6) 99 (63.1)  
 Grade II – V 12 (16.4) 58 (36.9) 0.002 
Post-pancreatectomy haemorrhage3 No 69 (94.5) 132 (85.4)  
 Grade A 0 (0.0) 2 (1.3)  
 Grade B 3 (4.1) 11 (7.0)  
 Grade C 1 (1.4) 12 (7.6) 0.044 
Cardiorespiratory complications2 Grade 0 – I  57 (80.3) 124 (78.0)  
 Grade II – V  14 (19.7) 35 (22.0) 0.695 
Wound infections2 Grade 0 – I  65 (89.0) 129 (82.2)  
 Grade II – V  8 (11.0) 28 (17.8) 0.183 
Readmission to critical care No 62 (84.9) 121 (77.1)  
 Yes 11 (15.1) 36 (22.9) 0.157 
Invasive intervention No 63 (86.3) 113 (72.0)  
 Yes 10 (13.7) 44 (28.0) 0.017 
Reoperation No  68 (93.2) 131 (83.4)  
 Yes 5 (6.8) 26 (16.6) 0.045 
Length of stay (days)4 Critical Care 6.0  (4.5 – 21.5) 7.0  (5.0 – 10.0) 0.0325 
 Overall  13.0  (9.0 – 21.5) 16.0  (12.0 – 27.0) 0.0025 
Readmission (30-day) No 64 (87.7) 119 (75.8)  
 Yes 9 (12.3) 38 (24.2) 0.038 
Mortality (90-day) 1 (1.4) 9 (5.7) 0.132 
Pancreas-specific complications includes postoperative pancreatic fistula and/or intra-abdominal collections.  
1 Chi-squared test.  
2 Grade refers to Dindo-Clavien classification of generic complications.  
3 Refers to ISGPS grade. Grades B/C were classed as clinically relevant. 
4 Median, inter-quartile range.  
5 Mann-Whitney U test.  
 Table 3. Multivariable logistic regression analysis for clinically relevant pancreas-specific 
complications (n = 230). 
 Variable Odds Ratio (95% CI) P 
Model A Pancreatic duct diameter (≤ 3mm) 1.43 (0.71 – 2.85) 0.317 
 Pancreatic texture (soft) 3.62 (1.97 – 6.65) <0.001 
    
Model B Pancreatic duct diameter (≤ 3mm) 1.19 (0.56 – 2.54) 0.648 
 Pancreatic texture (soft) 2.51 (1.23 – 5.11) 0.011 
 PoD0 serum amylase (≥ 130 IU/L) 3.72 (1.84 – 7.53) <0.001 
    
Model C Pancreatic duct diameter (≤ 3mm) 1.02 (0.50 – 2.10) 0.947 
 Pancreatic texture (soft) 2.36 (1.22 – 4.56) 0.011 
 PoD0 serum amylase (≥ 130 IU/L) 3.17 (1.64 – 6.12) 0.001 
 PoD2 serum CRP (≥ 180 mg/L) 2.39 (1.10 – 5.51) 0.026 
 
  
  
Supplementary Table 1. The relationship between serial serum CRP levels and (A) Clinically Relevant 
Postoperative Pancreatic Fistula and (B) Clinically Relevant Pancreas-specific Complication (n = 230).  
Serum CRP (mg/L)1 
 Study Cohort  Postoperative Pancreatic Fistula Pancreas-Specific Complication 
Day 
 
N (%) 
230 (100%) 
Absent 
N (%) 
176 (76.5) 
Present 
N (%) 
54 (23.5) 
P2 
Absent 
N (%) 
135 (58.7) 
Present 
N (%) 
95 (41.3) 
P2 
Pre-Op 6 (3 – 16) 6 (3 – 16) 6 (2 – 16) 0.648 6 (3 – 16) 6 (3 – 16) 0.793 
0 24 (14 – 40) 24 (13 – 40) 25 (14 – 38) 0.926 24 (13 – 41) 25 (14– 39) 0.961 
1 121 (87 – 154) 120 (84 – 153) 123 (104 – 164) 0.115 117 (83– 149) 123 (102 – 165) 0.093 
2 216 (162 – 270) 209 (147 – 260) 257 (195 – 303) <0.001 208 (141 – 247) 245 (188 – 289) <0.001 
3 186 (138 – 258) 173 (130 – 245) 232 (182 – 291) <0.001 169 (121 – 242) 223 (169 – 274) <0.001 
4 148 (92 – 219) 130 (83 – 206) 196 (141 – 272) <0.001 119 (76 – 202) 177 (129 – 247) <0.001 
5 115 (62 – 199) 103 (55 – 175) 167 (111 – 241) <0.001 93 (47 – 153) 159 (101 – 225) <0.001 
6 109 (56 – 178) 87 (49 – 167) 170 (103 – 241) <0.001 78 (43 – 162) 159 (96 – 219) <0.001 
7 107 (57 – 177) 91 (44 – 156) 172 (109 – 248) <0.001 73 (29 – 129) 167 (105 – 229) <0.001 
1 Median (Inter-quartile range).  
2 Mann-Whitney U test.  
Clinically relevant (CR) pancreas-specific complication including CR - POPF, CR - PPH and CR - IAC. 
Supplementary Table 2. Univariable predictors of clinically relevant pancreas-specific 
complications (CR-PSC) in patients undergoing pancreaticoduodenectomy (n = 230). 
 
Variable OR (95% CI) P 
Preoperative factors 
  Age (years) 
  ≤ 60   
  > 60 1.10 (0.65 – 1.87) 0.725 
  Sex 
  Female   
  Male 1.58 (0.90 – 2.78) 0.113 
  BMI (kg/m2) 
  < 25    
  ≥ 25  1.51 (0.88 – 2.60) 0.136 
  Smoking 
  No   
  Yes 1.03 (0.58 – 1.84) 0.928 
  POSSUM Score 
  < 16   
  ≥ 16 1.23 (0.71 – 2.12) 0.464 
  Bilirubin (mmol/L) 
  ≤ 250   
  > 250 1.06 (0.50 – 2.23) 0.888 
  Preoperative Biliary Drainage 
  No   
  Yes 0.66 (0.39 – 1.12) 0.657 
  ASA 
  I - II   
  III - IV 0.69 (0.32 – 1.46) 0.325 
Intraoperative Factors 
  Vein Resection 
  No   
  Yes 1.25 (0.62 – 2.54) 0.532 
  Pancreatic Texture 
  Hard   
  Soft 3.79 (2.07 – 6.95) <0.001 
  Pancreatic Duct Diameter (mm) 
  > 3   
  ≤ 3 2.18 (1.25 – 3.82) 0.006 
  Pancreatic Anastomosis 
  Pancreaticogastrostomy   
  Pancreaticojejunostomy 1.05 (0.55 – 1.99) 0.885 
  Estimated blood loss (ml) 
  < 1450   
  ≥ 1450  1.10 (0.64 – 1.90) 0.736 
  Pathology 
PDAC/ Chronic Pancreatitis   
  Other 1.37 (0.81 – 2.34) 0.245 
  PoD0 Serum Amylase (IU/L) 
  < 130   
  ≥ 130 5.20 (2.88 – 9.40) <0.001 
  PoD2 Serum CRP (mg/L) 
  < 180    
  ≥ 180 3.84 (1.84 - 6.59) <0.001 
 
 
  
Supplementary Table 3. Logistic regression analysis of pre-operative factors, intra-operative 
factors and serum markers as predictors of PoD2 serum CRP ≥ 180mg/L (n = 230). 
  Univariable Multivariable 
Variable n (%) OR 95% CI P OR 95% CI P 
Preoperative Factors 
Age (years)    
≤  60 100 (43.5)       
> 60 130 (56.5) 0.80 0.45 – 1.40 0.434    
Sex    
Female 79 (34.4)       
Male 151 (65.6) 1.54 0.86 – 2.73 0.143    
BMI (kg/m2)    
< 25 97 (42.2)       
≥  25 126 (54.8) 2.06 1.16 – 3.66 0.014    
Smoking     
No 137 (59.6)       
Yes 71 (30.9) 1.21 0.64 – 2.29 0.559    
POSSUM Score    
≤ 16 114 (49.6)       
> 16 97 (42.2) 1.48 0.82 – 2.67 0.197    
Bilirubin (mmol/L)    
≤ 250 197 (85.7)       
> 250 33 (14.3) 0.32 0.15 – 0.69 0.003    
Preoperative Biliary Drainage    
No 129 (56.1)       
Yes 101 (43.9) 1.40 0.79 – 2.46 0.248    
ASA 
I - II 165 (71.7)       
III - IV 37 (16.1) 0.675 0.32 – 1.41 0.294    
Intraoperative Factors 
Vein Resection    
No 193 (83.9)       
Yes 37 (16.1) 0.723 0.35 – 1.50 0.386    
Pancreatic Texture    
Hard 99 (43.0)       
Soft 94 (40.9) 2.51 1.33 – 4.74 0.005    
Pancreatic Duct Diameter (mm)    
> 3  142 (61.8)       
≤  3 81 (35.2) 3.41 1.72 – 6.74 < 0.001 2.53  1.12 – 5.68 0.025 
Pancreatic Anastomosis    
Pancreaticogastrostomy 50 (21.7)       
Pancreaticojejunostomy 175 (76.1) 0.61 0.30 – 1.24 0.172    
Estimated blood loss (ml)    
≤ 1450 121 (56.3)       
> 1450 94 (43.7) 1.50 0.82 – 2.72 0.187    
Pathology    
PDAC/ Chronic Pancreatitis 100 (43.5)       
Other 130 (56.5) 2.74 1.55 – 4.85 0.001    
Serum Markers 
PoD0 Serum Amylase (IU/L)    
< 130  123 (57.5)       
≥ 130         91 (42.5) 4.82            2.38 – 9.76  < 0.001 3.49  1.53 – 7.93   0.003 
Supplementary Table 4. The relationship between PoD0 serum amylase, PoD2 serum CRP, and 
postoperative complications after pancreaticoduodenectomy  
Variable  Low Risk Intermediate Risk  High Risk  
n = 214 n (%) 52 (22.6) 
n (%) 
83 (38.8) P   
2 n (%) 79 (36.9) P  
3 
Pancreatic Consistency 
 Hard 40 (76.9) 49 (59.0)  15 (19.0)  
 Soft 12 (23.1) 34 (41.0) 0.034 64 (81.0) <0.001 
Pancreatic Duct Size (mm) 
 > 3 42 (82.4) 52 (63.4)  25 (31.6)  
 ≤ 3 9 (17.6) 30 (36.6) 0.020 54 (68.4) <0.001 
Estimated Blood Loss (ml) 
 < 1450 33 (63.5) 48 (57.8)  43 (54.4)  
 ≥ 1450 19 (36.5) 35 (42.2) 0.517 36 (45.6) 0.664 
Pathology 
 PDAC/Chronic pancreatitis 31 (59.6) 39 (47.0)  20 (25.3)  
 Other 21 (40.4) 44 (53.0) 0.155 59 (74.7) 0.004 
Pancreas Specific Complications1  
 Grade 0 – I  45 (86.5) 54 (65.1)  27 (34.2)  
 Grade II – V 7 (13.5) 29 (34.9) 0.006 52 (65.8) <0.001 
Postoperative Pancreatic Fistula1 
 Grade 0 – I  51 (98.1) 67 (80.7)  44 (55.7)  
 Grade II – V 1 (1.9) 16 (19.3) 0.003 35 (44.3) 0.001 
Post Pancreatectomy Haemorrhage1 
 Grade 0 – I  51 (98.1) 74 (89.2)  65 (82.3)  
 Grade II – V 1 (1.9) 9 (10.8) 0.055 14 (17.7) 0.211 
Intra-abdominal Collection1 
 Grade 0 – I  46 (88.5) 65 (78.3)  40 (50.6)  
 Grade II – V 6 (11.5) 18 (21.7) 0.135 39 (49.4) <0.001 
Cardiorespiratory  Complications1 
 Grade 0 – I  46 (88.5) 69 (83.1)  57 (72.2)  
 Grade II – V 6 (11.5) 14 (16.9) 0.398 22 (27.8) 0.094 
Wound Complications1  
 Grade 0 – I  47 (90.4) 72 (86.7)  63 (79.7)  
 Grade II – V 5 (9.6) 11 (13.3) 0.526 16 (20.3) 0.234 
Admissions to Critical Care (episodes) 
   1 49 (94.2) 67 (80.7)  53 (67.1)  
 >1 3 (5.8) 16 (19.3) 0.029 26 (32.9) 0.048 
Invasive Intervention 
 
 
No 48 (92.3) 66 (79.5)  50 (63.3)  
Yes 4 (7.7) 17 (20.5) 0.047 29 (36.7) 0.022 
Reoperation 
 No  50 (96.2) 75 (90.4)  61 (77.2)  
Yes 2 (3.8) 8 (9.6) 0.213 18 (22.8) 0.023 
Length of Postoperative Hospital Stay (days) 
 ≤ 15 45 (86.5) 57 (68.7)  37 (46.8)  
 > 15 7 (13.5) 26 (31.3) 0.019 42 (53.2) 0.005 
Length of Critical Care Stay (days) 
 ≤ 7 39 (75.0) 43 (51.8)  30 (38.0)  
 > 7 13 (25.0) 40 (48.2) 0.007 49 (62.0) 0.084 
Readmission 
 No 46 (88.5) 64 (77.1)  60 (75.9)  
 Yes 6 (11.5) 19 (22.9) 0.115 19 (24.1) 1.000 
Mortality (90-day) 
 No 52 (100.0) 81 (97.6)  72 (91.1)  
 Yes 0 2 (2.4) 0.261 7 (8.9) 0.074 
 1 Refers to Dindo-Clavien classification of postoperative complications.  
2 Intermediate compared to Low Risk patients. 
3 High compared to Intermediate Risk patients. 
N = 214, 16 patients did not have PoD0 serum amylase measured. 
Low Risk:  PoD0 serum amylase < 130 IU/L AND PoD2 serum CRP <180 mg/L 
Intermediate Risk:  PoD0 serum amylase <130 IU/L AND PoD2 serum CRP ≥180 mg/L OR  PoD0 serum amylase 
≥ 130 IU/L AND PoD2 <180 mg/L 
 


